Category
Primary
pharmaceutical-drugs · embed-ft 0.77
Tree path
Medical Health › Pharmaceutical Drugs
Group (tier-1)
Tech stack
AI readiness
AI training policy
allowed
AI-bot protection
AI files
Evidence
llms.txt
Compliance (GEO / GDPR)
TLD
Overview
Title
Retatrutide: The Triple-Agonist Trial Record — A Research Digest
Description
Retatrutide (LY3437943) is an investigational triple agonist at GIP, GLP-1, and glucagon receptors — Phase 2 data show mean -24.2% body weight at 12 mg over 48 weeks. A cited digest of the published literature.
Final URL
Language
en (html)
Scanned at
2026-06-26 12:27:13